Search verified investigators and sites
By specialty, location, and readiness.
CMBH Research Intelligence In development
From Research Opportunity to Clinical Evidence
An AI-assisted research intelligence and site-matching platform in development.
Current status: in development. No working functionality is claimed on this site. Everything below describes the planned platform. It is decision support, and human scientific and regulatory oversight remains essential.
Proposed capabilities
What the platform is intended to do
Match protocols to capabilities
Match protocol requirements to site capabilities and eligible patient populations.
Analyze evidence and unmet needs
Analyze published research, unmet needs, and appropriately authorized aggregate population signals to suggest future research questions.
Track feasibility and operations
Track feasibility, enrollment, and operations with human review.
Support sponsor decisions
Help sponsors decide what to study, where, and with whom.
Two planned workflows
How it would be used
Sponsor-initiated
Match a proposed protocol to qualified investigators, sites, and feasible patient populations.
CMBH-originated
Suggest promising research questions to sponsors from published research, unmet needs, authorized aggregate signals, and investigator feedback.
- 01
Evidence and need
Scientific evidence and unmet-need signals.
- 02
AI-assisted analysis
Opportunity analysis to surface candidates.
- 03
Feasibility matching
Investigator and site feasibility matching.
- 04
Human scientific review
Qualified people review every recommendation.
- 05
Protocol development
Sponsor protocol development with qualified partners.
- 06
Execution and learning
Coordinated execution, then lawful learning and dissemination.
The platform is intended to recommend, not to make autonomous medical or regulatory decisions. It would use only authorized data, document data provenance, protect privacy, assess bias, and validate recommendations with qualified humans. It does not imply access to medical records, use of identifiable patient data without permission, or validated AI predictions. Observed patient populations are not the same as verified trial eligibility, demand, commercial market size, or efficacy.